MGC And GlycoNex Kick Off Denosumab Trial In Japan
Partners Also Eye Global Markets For Biosimilar Rival To Prolia And Xgeva
Executive Summary
Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.